ProVee System for BPH
Proverum, Ltd. · Decision date Dec 9, 2025
What did the FDA approve?
FDA records P250011 as an original PMA application. The recorded decision is approval, dated Dec 9, 2025.
FDA approval order statement
The ProVee System for BPH is intended for the treatment of obstructive lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) in men with prostatic urethral lengths greater than or equal to 3.75 cm and prostatic volumes between 30 and 80 cc.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Dec 9, 2025
Regulatory record facts
- Identifier
- P250011
- Regulatory pathway
- Premarket approval application
- Applicant
- Proverum, Ltd.
- Product code
- MER
- Decision code
- APPR
- Decision date
- Dec 9, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT.
- Applicant
- Proverum, Ltd.
- Product code
- MER
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250011 received
Application receipt date recorded by FDA.
P250011 · FDA decision
APPR
P250011/S006 · Related supplement
ProVee System for BPH
P250011/S005 · Related supplement
ProVee System for BPH
Timeline entries are records held by MedtechLedger for P250011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ProVee System for BPHP250011/S006 | Proverum, Ltd. | PMA supplement | Sep 24, 2026 | FDA |
ProVee System for BPHP250011/S005 | Proverum, Ltd. | PMA supplement | Nov 3, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Proverum, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2nd Floor Astor Hall, 4-8 Eden Quay, Dublin, D01N5W8
Sources and methodology
- Original FDA record: P250011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
